Kelyniam Global Inc., a leading manufacturer of custom cranial and craniofacial implants, reported its financial results for the second quarter ending June 30, 2025. The company experienced a 20.2% decrease in total revenue, amounting to $1.364 million compared to $1.709 million in the same period in 2024. The gross margin also declined by 18.1%, reaching $1.091 million from $1.331 million the previous year. Kelyniam reported an operating loss of $59,869, a significant shift from an operating profit of $172,093 in Q2 2024. CEO Ross Bjella highlighted improvements over Q1 2025 results, attributing the gains to focused sales execution and efforts to capitalize on available opportunities in the cranial implant market. Despite the decrease in revenue compared to the previous year, Kelyniam saw increased sales in the latter part of Q2, driven by a strategic focus on sales activities leading into the trauma season. The company's annual shareholder meeting was held on June 23rd, with all official business matters passing with record participation levels. Further financial details are available on Kelyniam's website.